Opinion|Videos|January 3, 2025
Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Panelists discuss how recent trials evaluating quadruplet regimens in transplant-ineligible/deferred NDMM, including IMROZ and BENEFIT, demonstrate promising efficacy with isatuximab-VRd combinations showing comparable MRD negativity rates to CEPHEUS’ daratumumab-VRd data, though cross-trial comparisons require careful interpretation.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on other quadruplet regimens in the TIE or deferred NDMM space.
- Briefly discuss IMROZ(isatuximab [Isa]-VRd vs VRd)
- IMROZ, MRD negativity
- Briefly discuss BENEFIT (Isa-VRd vs Isa-Rd)
- Thinking back to CEPHEUS, how do data from these trials compare?
Advertisement
Related to this article
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
2
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
3
MYTHOS Misses Prespecified ORR End Point With T-DXd in HER2-Low Salivary Gland Carcinoma
4
Dr Ermann on Real-World Data for Zanubrutinib vs Acalabrutinib in Older CLL
5